Phase 2 Study With Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
Patients with Anaplastic Thyroid Cancer have a poor prognosis. We will treat the patients
initially with our standard radiochemotherapy, which consists of doxorubicin 20mg fixed
dose/week and hyperfractionated radiotherapy 1,6 Gy twice daily up to 46 Gy in total. The
first week during radiotherapy, they will also receive Avastin 15mg/kg. 1-2 weeks after
radiotherapy patients will undergo surgery of their primary tumor. After this "standard"
therapy patients can be included in this study. Treatment is 20 mg fixed dose doxorubicin
q1w and avastin 15mg/kg q3w. Treatment will continue maximum 6 months or until progress or
until intolerable side effects occur.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall Survival
2-5 years
No
Jan Tennvall, MD, PhD
Principal Investigator
Dep of Oncology, Lund University Hospital
Sweden: Medical Products Agency
2007-001783-75
NCT00804830
April 2008
December 2014
Name | Location |
---|